Ownership
Public
Employees
~500
Stage
Commercial
Modalities
Autologous cell therapyGene therapySmall molecule

Evogene General Information

Multiple subsidiaries advancing products in human health, agriculture and industrial applications using computational biology platform. Biomica has Phase 1 trial for microbiome-based immuno-oncology drug BMC128.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

BMC128
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Evogene's pipeline data

Book a demo

Key Partnerships

Bayer, DuPont Pioneer, Monsanto, BASF, Corteva Agriscience, Google Cloud

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Evogene Funding

Deal TypeDateAmountStatusStage
Later Stage VCAug 23, 2024$5.5MCompletedCommercial
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Evogene's complete valuation and funding history, request access »

Evogene Licensing Deals

AssetLicenseeDateTherapeutic Area
axoguard nerve connectorAxogenAug 1, 2008Neurology
axoguard nerve protectorAxogenAug 1, 2008Neurology
axoguard nerve capAxogenJun 27, 2017Neurology
ha+AxogenMay 2, 2023Neurology
You're viewing 2 of 4 licensing deals. Get the full list »